TGF-b can act as a tumor suppressor at early stages of cancer progression and as a tumor promoter at later stages. The E3 ubiquitin ligase Arkadia (RNF111) is a critical component of the TGF-b signaling pathway, being required for a subset of responses, those mediated by Smad3-Smad4 complexes. It acts by mediating ligandinduced degradation of Ski and SnoN (SKIL), which are 2 potent transcriptional repressors. Here, we investigate the role of Arkadia in cancer using model systems to address both potential tumor-suppressive and tumorpromoting roles. Stable reexpression of Arkadia in lung carcinoma NCI-H460 cells, which we show contain a hemizygous nonsense mutation in the Arkadia/RNF111 gene, efficiently restored TGF-b-induced Smad3-dependent transcription, and substantially decreased the ability of these cells to grow in soft agar in vitro. However, it had no effect on tumor growth in vivo in mouse models. Moreover, loss of Arkadia in cancer cell lines and human tumors is rare, arguing against a prominent tumor-suppressive role. In contrast, we have uncovered a potent tumor-promoting function for Arkadia. Using 3 different cancer cell lines whose tumorigenic properties are driven by TGF-b signaling, we show that loss of Arkadia function, either by overexpression of dominant negative Arkadia or by siRNA-induced knockdown, substantially inhibited lung colonization in tail vein injection experiments in immunodeficient mice. Our findings indicate that Arkadia is not critical for regulating tumor growth per se, but is required for the early stages of cancer cell colonization at the sites of metastasis. Cancer Res; 73(6); 1800-10. Ó2012 AACR.
Introduction
The TGF-b signaling pathway has a dual role in tumorigenesis (1, 2) . It can function as a tumor suppressor by inhibiting cell growth, inducing apoptosis, promoting differentiation, as well as acting on the stroma to suppress inflammation and the production of mitogens (2) . Conversely, TGF-b can support tumor development by inhibiting immune responses and by regulating processes necessary for the colonization of distant tissues, such as angiogenesis, cancer cell migration, and invasion (2, 3) . At later stages of tumorigenesis, the TGF-b signal is a major contributor to the transcriptional regulation of genes necessary for cancer cell migration and invasion, as well as microenvironment remodeling (3, 4) . TGF-b binds and activates complexes of serine/threonine kinase receptors comprising TbRII and TbRI (ALK5) at the cell surface. This leads to phosphorylation of receptor-regulated Smads, of which the best understood are Smad2 and Smad3 (5) . These activated Smads complex with Smad4 and accumulate in the nucleus where they directly regulate the transcription of target genes (6) . Ski and SnoN are potent transcriptional corepressors that inhibit the transcription of a subset of TGF-b-responsive genes (7) . In the absence of TGF-b, Ski and SnoN bind Smad-binding elements (SBE) in the promoters/ enhancers of target genes together with Smad4, forming a transcriptional repressor complex with histone deacetylases to silence basal transcription (8) (9) (10) (11) (12) (13) (14) (15) . The particular elements recognized by Ski and SnoN are those recognized by Smad3-Smad4 complexes, and also complexes of Smad4 with a splice form of Smad2, Smad2Dexon3 (12) . In response to TGFb, Ski and SnoN are rapidly degraded via the ubiquitinproteasome pathway (8) . This degradation allows the phosphorylated Smad3/Smad2Dexon3-containing complexes to bind SBEs in the promoters/enhancers of target genes (7, 8, 12) .
While several ubiquitin ligases, namely Smurf2 and the anaphase-promoting complex, were originally proposed to be responsible for regulating Ski and SnoN levels, (16) (17) (18) , several years ago, we and others established that the E3 ubiquitin ligase Arkadia (encoded by the RNF111 gene) was required for TGF-b-induced SnoN and Ski degradation (12, 19, 20) . We showed that in response to TGF-b, Arkadia interacts with SnoN and phosphorylated Smad2/Smad3, and this is necessary for SnoN degradation (12) . As a result, Arkadia is essential for a subset of TGF-b-induced transcriptional responses, those mediated via Smad3/Smad2Dexon3.
Like the TGF-b pathway itself, SnoN also plays a dual role in cancer (21) . Because Arkadia is a critical modulator of Ski and SnoN levels, deregulation of Arkadia function might be predicted to influence tumor development and/or dissemination. We previously described a lung carcinoma cell line, NCI-H460 (originally wrongly classified as the esophageal carcinoma cell line SEG-1; ref. 22 ) that lacked functional Arkadia, and hence did not exhibit TGF-b-induced SnoN degradation, and was deficient in Smad3-dependent transcriptional responses (12) . We hypothesized that Arkadia might be a novel tumor suppressor, with specific loss of the Smad3/Smad2Dexon3-dependent arm of the TGF-b pathway through loss of Arkadia allowing cells to evade the tumor suppressive effects of TGF-b, while maintaining TGF-b's tumor-promoting activities (12) . Consistent with this, Arkadia þ/À heterozygous mice are more susceptible to developing tumors in a colorectal tumor model after exposure to carcinogen, compared with wild-type mice (23) . However, there was no evidence that the other allele of Arkadia was lost in these tumors, as might be expected for a classical tumor suppressor. Moreover, although a number of mutations in Arkadia were found in primary colorectal tumors from human patients, only one of them clearly resulted in a nonfunctional protein (23) . An alternative possibility to the idea of the 2 arms of the TGF-b pathway having different functions in cancer is that the pathway as a whole may have both tumor-suppressive and tumor-promoting functions, but which predominates depends on the context. If this were the case, then Arkadia, like SnoN and Smad4 (2, 21, 24, 25) , might be expected to exhibit a dual role in cancer.
Here, we dissect the role of Arkadia in tumorigenesis, using 2 model systems designed to examine both potential tumorsuppressor and tumor-promoting activities. Our data do not support a prominent tumor-suppressive role. Instead, we show that Arkadia is required for metastasis, probably at the level of extravasation.
Materials and Methods

Plasmids
The following plasmids were previously described: HASnoN, HA-Smad3, FLAG-Arkadia, CAGA 12 -Luciferase and TK-Renilla (12), and HA-Ski (9) . To make the stable cell lines, wild-type Arkadia and Arkadia C937A (12) were subcloned into the 3 Â Flag pBICEP-CMV2 vector (Sigma). FLAG-Arkadia 1-440 was generated by introducing a stop codon at amino acid 441 in the FLAG-Arkadia construct (12) .
Cell lines and cell treatments
HaCaT, MDA-MB-231, 293T, B16, CACO-2, and HT-29 cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) containing 2 mmol/L glutamine and 10% fetal calf serum (FCS). NCI-H460 and COLO-205 cells were cultured in RPMI-1640 supplemented with 2 mmol/L glutamine and 10% FCS. MTLN3E cells were cultured in Alpha Minimum Essential Medium containing 2 mmol/L glutamine and 10% FCS. HT-55 cells were cultured in a 1:1 mix of DMEM and RPMI containing 2 mmol/L glutamine and 10% FCS. Primary human umbilical vein endothelial cells (HUVEC; CC-2517, Lonza,) were grown in collagen-precoated flasks (BD Biocoat) in EGM-2 BulletKit media with supplements (CC-3162, Lonza) at 5% CO 2 . Stable cell lines were obtained by transfecting NCI-H460 or MDA-MB-231 cells with either pBICEP-CMV2-FLAG-Arkadia or pBICEP-CMV2-FLAG-Arkadia-C937A, respectively, and selecting clones with G418 (Gibco). MDA-MB-231 cells expressing GFP or mCherry were generated by transfecting pEGFP-N1 and pCherry-N1 plasmids (Clontech) into MDA-MB-231 cells, selecting with 500 mg/mL G418 (Gibco) and by fluorescence-activated cell sorting (FACS). The B16 cells were labeled with Cherry or enhanced GFP (EGFP) in the same way. The MTLN3E cells were labeled using lentivirus containing either myr-GFP or myr-Cherry and were FACS sorted. The MDA-MB-231 Arkadia C937A clones were labeled with a membraneassociated GFP (GFP-CAAX) using the lentivirus system and were selected with blasticidin.
Cells were stimulated with 2 ng/mL of TGF-b (Peprotech EC Ltd.) for the specified times. The ALK5 inhibitor SB-431542 (Tocris) was used at 10 mmol/L. For proteasome inhibition, cells were treated with 50 mmol/L of MG132 (Tocris) for 4 hours.
Immunoprecipitations, Western blot analyses, antibodies, and luciferase assays
Whole-cell extracts were prepared either using radioimmunoprecipitation assay buffer (12) or as described (26) . Western blot analyses were conducted following standard procedures. For transmembrane prostate androgen-induced (TMEPAI) blots, extracts were treated with PNGase as described (27) . Antibodies are listed in the Supplementary Methods. Immunoprecipitations and luciferase assays were as described (12) . For luciferase assays, TGF-b induction was for 8 hours.
Xenografts and tail vein injection assays
For xenografts, cells were trypsinized and 5 Â 10 6 cells were resuspended in 100 mL PBS and injected subcutaneously into the right and left flanks of approximately 6-week-old female, Balb/c nu/nu mice (4 mice per condition). Tumor growth was measured with external calipers every 2 or 3 days for a maximum of 6 weeks.
For tail vein injections with unlabeled cells, the cells were trypsinized and 1 Â 10 6 cells were injected into the tail vein of Balb/c nu/nu mice (4 or 5 mice per condition). Lungs were removed at 20 or 30 days postinjection and fixed in neutralbuffered formalin. Three sections corresponding to different levels of the lungs were obtained, which were stained with hematoxylin and eosin. The number of tumors in each slide was determined by a pathologist. For the tail vein injections with fluorescent cells, 1 Â 10 6 cells of a 1:1 mixture GFP-and mCherry-expressing cells (where either both were controls or one an experimental sample and the other a control) were injected into the tail vein of 6-week-old female, ICRF nu/nu mice (MDA-MB-231 and B16) or Balb/c nu/nu (MTLN3E). Additional controls for the ratio of mCherry and GFP cells were conducted by seeding 10 mL of the cell suspension into a glass-bottom dish coated with poly-lysine (Sigma); after 2 hours, cells were fixed in 4% paraformaldehyde and imaged with a Zeiss LSM 780 confocal microscope using a PlanNeofluar 10 Â 0.3 objective. Forty-eight hours after injection, the mice were culled, lungs extracted, and representative images of the tumor distribution were analyzed by confocal microscopy. The area occupied by fluorescent tumor cells was calculated using Volocity software (PerkinElmer) and the GFP: mCherry ratio calculated using the total area of the green and the red cells and was normalized using the GFP:mCherry ratio observed in the control plates.
Cell line origin and authentication
The parental MDA-MB-231 cells were obtained from the ECACC/HPA culture collection and were banked at Cancer Research UK Cell Services. The MDA-MB-231 cells expressing Arkadia C937A were derived from these cells. These cell lines were authenticated using the short tandem repeat profiling and isoenzyme analysis. The NCI-H460 cells were obtained from the American Type Culture Collection and were banked at Cancer Research UK Cell Services. The Arkadia-expressing clones were derived from these cells. The MTLN3E cells were obtained from John Condeelis (Albert Einstein College of Medicine, Bronx, NY). We have proven that they are syngeneic with Fisher 344 rats in agreement with their published history (28) . The B16 cells were obtained from Cancer Research UK Cell Services. We have proven that they are syngeneic with C57BL/6 mice and produce pigment consistent with their published history (29) . All cell lines were frequently tested for mycoplasma and were negative.
For genomic sequencing, RNA-seq, quantitative PCR (qPCR), soft agar, and cell-cycle analyses, cell spreading and cell adhesion assays, and lists of primers, antibodies, and siRNAs, see Supplementary Methods.
Results
NCI-H460 cells express a truncated version of Arkadia that is catalytically inactive and are deficient in TGFb-induced Smad3-dependent transcription
To investigate whether Arkadia might be a novel tumor suppressor gene, we used a lung cancer cell line, NCI-H460, that we previously showed had lost expression of full-length Arkadia (12) . Although NCI-H460 cells express Arkadia mRNA (Fig. 1A) , they do not express full-length Arkadia protein.
However, a faster migrating band was observed in extracts from these cells, that was absent in HaCaT extracts, suggesting that they might express a truncated version of Arkadia ( To investigate the biological relevance of this mutation, we tested the ability of this truncated Arkadia to interact with Ski, SnoN, and Smad3 (12, 19, 20) . very weakly interacted with Ski. However, it still retained its ability to interact with Smad3 ( Fig. 1C) . To assay the activity of Arkadia 1-440, we compared its ability to rescue CAGA 12 -luciferase activity in the NCI-H460 cells with that of wild-type Arkadia and a dominant negative Arkadia, which has a point mutation in the RING domain (C937A; ref. 12). Arkadia 1-440 was substantially less active than wild-type Arkadia, showing only residual activity comparable with that of Arkadia C937A (Fig. 1D ). In 293T cells, which contain endogenous Arkadia, Arkadia 1-440 had very little activity, compared with wild-type Arkadia (Fig. 1D ). However, unlike Arkadia C937A, it did not exhibit dominant negative activity, probably as a result of losing its ability to interact with Ski and SnoN.
Reintroduction of functional Arkadia in NCI-H460 cells restores specific TGF-b responses and inhibits anchorage-independent growth, but has no effect on tumor growth in vivo To determine whether loss of Arkadia in NCI-H460s might be responsible for their tumorigenic phenotype, we investigated the effect of restoring Arkadia function. We generated 2 cell lines (WT Ark 1 and WT Ark 11) that stably express FLAG-tagged Arkadia ( Fig. 2A) . Treatment of cells with the proteosome inhibitor MG132 increased protein levels of overexpressed Arkadia in these NCI-H460 cell lines and also endogenous Arkadia in control MDA-MB-231 cells, indicating that Arkadia is normally unstable, probably due to autoubiquitination ( Fig.  2A and Fig. 3A; ref. 12 ). In both WT Ark 1 and WT Ark 11 cells, Figure 2 . Reintroduction of Arkadia in NCI-H460 cells restores TGF-b-dependent Ski/SnoN degradation, transcriptional responses, and inhibits anchorage independent growth, but has no effect on their tumorigenic properties in vivo. A, Western blot analysis showing Arkadia levels in 2 NCI-H460-derived cell lines expressing FLAG-tagged Arkadia. Cells were treated for 4 hours AE MG132. Actin is a loading control. B, whole-cell extracts from cells treated AE TGF-b Western blotted using the antibodies indicated. C, luciferase assays were conducted as in Fig. 1 . D, whole-cell extracts prepared from the cell lines indicated and Western blotted using antibodies shown. E, NCI-H460 parental cells or the clones expressing FLAG-tagged Arkadia were grown in soft agar for 10 days. The numbers of colonies were quantified and are shown in the bar graph (right). F, the cell lines shown were injected subcutaneously in both flanks of Balbc nu/nu mice. The data are the averages of the tumor volumes for 4 mice (8 tumors in total) per cell line. (Fig. 2B ) and Smad3-dependent transcription (Fig. 2C) . Induction of the TGF-b-dependent gene, transmembrane prostate androgen-induced RNA (TMEPAI; ref. 30) , was also recovered after reintroduction of Arkadia (Fig. 2D) .
Tumor-suppressive effects of the TGF-b pathway are thought to be at least partly mediated by effects on cell growth (2). However, we found no effect of Arkadia reintroduction into NCI-H460 cells on the rate of cell proliferation in vitro in the presence or absence of TGF-b (Supplementary Fig. S2 ). We next determined whether restoring Arkadia altered the transformed phenotype of NCI-H460 cells in vitro by conducting soft-agar assays, which measure anchorage-independent growth. NCI-H460 cells formed colonies in soft agar (Fig.  2E ). This growth depends on autocrine TGF-b signaling, as it was abolished by SB-431542, a specific inhibitor of the TGF-b type I receptor (data not shown; ref. 31) . Exogenous TGF-b could not further promote colony formation, suggesting that the autocrine TGF-b activity in these cells is sufficient. Because the cells lack Arkadia activity, this growth is Arkadia independent. Strikingly, neither of the NCI-H460 clones in which Arkadia has been reexpressed, were able to form a substantial number of colonies (Fig. 2E) . Thus, anchorage-independent growth of NCI-H460 cells is inhibited by Arkadia.
We went on to test whether restoring Arkadia activity in NCI-H460 cells had any effect on their tumorigenic properties in vivo. In xenograft assays in immunodeficient mice, primary tumor growth was not affected by Arkadia (Fig 2F) . We also investigated whether the ability of cells to colonize and develop tumors in distant tissues was affected by Arkadia activity by conducting tail vein injections in immunodeficient mice. However, no significant differences in the number of lung tumors derived from parental cells or from the clones expressing wildtype Arkadia were observed, either at 20 or 30 days postinjection (Supplementary Table S1 ). We conclude, therefore, that although restoration of Arkadia activity in NCI-H460 cells at least partly reversed the transformed phenotype in vitro, it does not affect tumorigenicity in vivo. This might be explained by the gain of additional driving mutations after acquisition of the Arkadia mutation. Mutations in Arkadia in human cancer are rare To obtain a more comprehensive view of Arkadia mutation frequency in human cancer, we analyzed Arkadia protein levels and TGF-b-induced SnoN degradation in a number of cancer cell lines of different tissue origin, focusing particularly on those identified from the Sanger Centre Cancer Genome Project (CGP) LOH and copy number analysis that displayed LOH at the 15q22.1 locus containing the Arkadia/RNF111 gene. We were unable to find another cancer cell line in which Arkadia was deleted or that contained a loss-of-function mutation in Arkadia (data not shown). Interestingly, we observed a direct correlation between loss of TGF-b-induced SnoN degradation and loss of Smad4 activity. Examples are the CACO-2 cell line, which contains a point mutation in Smad4 that renders it unable to form complexes with R-Smads (32), and the Colo-205 and HT-29 cell lines that are deleted for Smad4 (Supplementary Fig. S3 ). Thus mutation or deletion of Smad4, which is common in certain tumors, has the same inhibitory effect on SnoN degradation as loss of Arkadia (see Discussion).
Inhibition of Arkadia activity in MDA-MB-231 cells alters their adherence and ability to spread on endothelial cells
The evidence presented above does not support the idea that Arkadia is primarily a tumor suppressor. Moreover, cancer cell lines that exhibit LOH at the Arkadia locus do not lose or acquire mutations in the other allele, suggesting the possibility that Arkadia might be important for mediating TGF-b's tumorpromoting functions (2) . To address this, we chose a wellcharacterized breast cancer cell line MDA-MB-231 that requires TGF-b signaling for metastasis (24, (33) (34) (35) and investigated how loss of Arkadia activity affected its tumorigenic properties.
Overexpression of Arkadia C937A acts dominant negatively to suppress the activity of an endogenous Arkadia ( Fig. 1C;  ref. 12 ). We therefore used this construct to inactivate Arkadia in MDA-MB-231 cells (Fig. 3A) . Arkadia C937A prevented TGFb-induced Ski and SnoN degradation in 3 independent clones, ( Fig. 3B and Supplementary Fig. S4A ). To determine the effect of dominant negative Arkadia on TGF-b-regulated target genes at the genomic scale, we conducted RNA-seq at 1 hour and 24 hours after TGF-b stimulation. Supplementary Fig. S5 shows the filtered datasets presented as heatmaps and Supplementary Fig. S6 shows qPCR validations for selected genes. The similarity between the qPCR data and the RNA-seq data gave us confidence in the RNA-seq dataset as a whole. We identified 36 genes that are significantly (more than 2-fold) up or downregulated by TGF-b at 1 hour, 103 genes that are upregulated by TGF-b at 24 hours, and 70 genes downregulated by TGF-b at 24 hours (Supplementary Fig. S5 ). Consistent with (12), we found that a subset of TGF-b-responsive genes was strongly affected by dominant negative Arkadia, whereas other genes were only weakly affected, or not affected at all (Supplementary Fig. S5 ). Examples of strongly affected genes are the 2 well-characterized TGF-b targets, PAI-1 and TMEPAI (Fig. 3C) . This was corroborated at the protein level ( Fig. 3D and Supplementary Fig. S4B ). We conclude that expression of Arkadia C937A efficiently inhibits endogenous Arkadia function.
MDA-MB-231 cells are resistant to TGF-b-induced growth arrest (21) , and we noted an absence of genes involved in TGFb-induced cell-cycle arrest in the MDA-MB-231 cells in the RNA-seq analysis (Supplementary Fig. S5 ). Inactivation of Arkadia is therefore unlikely to affect cell growth. Indeed, we found no difference in the growth rate of parental or Arkadia C937A-expressing cells in vitro on plastic, in soft agar, or on the growth of these cells in xenograft assays in immunodeficient mice (data not shown), consistent with other studies showing that TGF-b signaling does not have a tumor-suppressive effect in MDA-MB-231 cells (34) .
To gain insight into the TGF-b-driven processes for which Arkadia is likely to be required, we conducted a MetaCore analysis of genes that significantly change in their TGF-b regulation between the parental and Arkadia C937A-expressing cells. This indicated an enrichment of genes involved in cell adhesion, cell matrix interactions, epithelial-to-mesenchymal transition (EMT) and ECM remodeling (Table 1) , and processes involved in tumor cell dissemination from primary tumors to sites of metastasis (36) . During metastasis, tumor cells enter the blood or lymphatic circulation (intravasation) and then extravasate at the site of metastasis (37) . Because both of these processes involve invasion through a layer of endothelial cells, we attempted to mimic this in vitro by assessing cell adhesion and ability to spread on a confluent layer of endothelial cells (HUVEC). To visualize the cells, we fluorescently labeled them with GFP and, in the case of the parental cells, also mCherry. Equal numbers of GFP-(parental or Arkadia C937A-expressing) and mCherry-labeled parental cells were plated onto a layer of HUVECs. We found that the Arkadia C937A-expressing cells adhered more strongly to the HUVEC cells than the parental MDA-MB-231 cells (Fig. 3E) . When the GFP-labeled cells were plated onto confluent layers of HUVEC cells and filmed over a period of hours to assess cell spreading (Supplemental Movies S1 and S2; ref. 38), we consistently observed an inhibition in the ability to spread of the Arkadia C937A-expressing cells compared with parental cells (Fig. 3F) . Thus, cells inhibited in Arkadia function are more adherent to endothelial cells, but have defects in spreading, possibly indicating a defect in remodeling of adhesions.
Inhibition of Arkadia activity in MDA-MB-231 cells inhibits colonization of lungs of immunodeficient mice
The reduced ability of cells lacking Arkadia activity to spread on endothelial cells suggested that Arkadia could play a role in metastasis. We tested this directly, and observed a robust inhibition of lung colonization of the 3 individual clones of MDA-MB-231 cells expressing Arkadia C937A, compared with parental cells in tail vein injection assays conducted over 20 days (Fig. 4A) . To determine whether Arkadia activity is important for early stages of lung colonization, we conducted these assays over a period of just 48 hours, using the fluorescently labeled cells described above. Mice were injected with a 1:1 ratio of GFP-and mCherry-labeled cells as described in the Materials and Methods, and after 48 hours, lung colonization was assessed. A dramatic decrease in the number of Arkadia C937A-expressing cells compared with the control mCherrylabeled parental cells was observed ( Fig. 4B; Fig. 4C ). Because the effects of dominant negative Arkadia were evident just 48 hours after tail vein injection, we concluded that Arkadia is required for early stage colonization. Taken together with the in vitro cell spreading and adhesion data, it is likely that Arkadia is required for extravasation.
Arkadia C937A is catalytically inactive, but retains its ability to interact with partners such as SnoN and Smad2/3 (12) . It was therefore important to exclude the possibility that the decrease in the efficiency of lung colonization by cells overexpressing Arkadia C937A was due to titration of some of Arkadia's partners. We therefore downregulated Arkadia in parental MDA-MB-231 cells using 2 different siRNAs and investigated the effect on short-term lung colonization. Knockdown of Arkadia was efficient for both siRNAs, and TGF-b-induced SnoN degradation was inhibited (Fig. 5A) , as was Smad3-dependent transcription (Fig. 5B) . In lung colonization assays, we observed a significant decrease (20%-30%) for the cells in which Arkadia was downregulated compared with control cells (Fig. 5C) .
Finally, to confirm that Arkadia acts as a tumor promoter, we extended our analysis to 2 further cell lines for which metastasis is known to be driven by TGF-b: the rat mammary carcinoma cell line MTLN3E (39) and the mouse B16 melanoma cell line (29) . In both cases, knockdown of Arkadia resulted in loss of TGF-b-induced Ski and SnoN degradation, reduction of Smad3-dependent transcription ( Supplementary Fig. S7) , and most importantly, substantial inhibition (between 66% and 78%) of lung colonization (Fig. 6) . 
Discussion
A role for Arkadia in tumorigenesis had been hypothesized since it was first described as the ubiquitin-ligase controlling the cellular levels of Ski and SnoN (12, 19, 20) . Here, we investigated a potential tumor suppressor function for Arkadia by restoring its activity in the NCI-H460 cell line that contains a hemizygous nonsense mutation. Although reexpression of Arkadia decreased the transformed phenotype of these cells in vitro, we found no effect on growth of tumors in xenograft assays, or in lung colonization assays. These results could indicate that the inactivating mutation we identified in Arkadia is not a cancer driver mutation (40) . However, it is also possible that loss of Arkadia constitutes an early priming event for tumorigenesis, and that acquisition of subsequent mutations in this cell line prevents the reexpression of Arkadia reversing the tumorigenicity of these cells in vivo. In support of this, another recent study concluded that Arkadia has tumor suppressive activity in colorectal cancer (23 Ã (of unknown zygosity), that would similarly delete the RING domain of Arkadia, have been found in tumors of the upper aerodigestive tract, large intestine, and hematopoetic and lymphoid tissue sequenced by the CGP at the Sanger Institute (reported in the COSMIC database) and in a colorectal tumor (23) . In addition, 4 missense mutations have also been reported in the COSMIC database, but how these mutations affect Arkadia function is unknown. These findings indicate that Arkadia mutations do occur in human cancer, but are rare.
It is well established that different components of the TGF-b pathway are mutated in cancer at different rates. Whereas inactivating mutations and deletions in Smad4 and TGFBR2 are common in certain cancers, mutations in ALK5, Smad2, and Smad3 are relatively rare (41) (42) (43) . Arkadia seems to be in this latter class. In our search for cell lines containing mutations in Arkadia, we made the unexpected discovery that deletion of Smad4, or acquisition of Smad4 mutations that abolish SmadSmad interactions also abolished TGF-b-induced degradation of SnoN, that is, it confers the same effect on Ski and SnoN levels as would loss of Arkadia. We therefore speculate that Figure 6 . MTLN3E and B16 cells require Arkadia to colonize lungs. A and B, GFP and mCherry-labeled MTLN3E cells or B16 cells were transfected with a control siRNA (NT), and GFP-labeled MTLN3E and B16 cells were transfected with siRNAs against Arkadia as indicated. Twenty-four hours later cells were split for immunoblots, qPCR for Arkadia/GAPDH, and 48-hour lung colonization mouse experiments, which were as described in Fig. 4. cancer cells may lose Smad4 in preference to Arkadia to achieve stabilization of Ski and SnoN.
The observation that cancer cells do not preferentially lose all Arkadia function led us to investigate whether it might play additional roles at later stages of tumorigenesis. To explicitly address this, we have used 3 different tumor cell lines that metastasize in a TGF-b-dependent manner (29, 34, 39) . Our results clearly show that Arkadia has a potent tumor-promoting activity. Arkadia inactivation has no effect on primary tumor growth, in agreement with previous work showing that manipulation of the TGF-b pathway in these cells had no effect on mammary tumor growth (34) . Instead, we show a dramatic effect of loss of Arkadia activity on lung colonization in tail vein injection experiments in immunodeficient mice. The fact that we can detect these effects within 48 hours, coupled with our observation that MDA-MB-231 cells expressing dominant negative Arkadia adhere more strongly than parental cells to a confluent layer of HUVEC cells, which mimics the capillary wall, and do not spread as efficiently, leads us to conclude that Arkadia is likely important for extravasation rather than growth and survival of the cells in the lungs.
Our RNA-seq analysis uncovered a large group of genes whose TGF-b regulation was perturbed by loss of Arkadia activity. Importantly, this list contained genes previously implicated in lung metastasis of MDA-MB-231 cells, such as ANGPTL4, Id1, LOX, and SNAI1 (refs. 33, 34, 44, 45; Supplementary Figs S5 and S6). We have used gene enrichment analysis to further define classes of genes that might be responsible for lung colonization and identified genes involved in cell adhesion, cell matrix interactions, EMT, and ECM remodeling as particularly affected by loss of Arkadia activity. Specific combinations of these genes are likely to be responsible for driving metastasis in this tumor model.
Our data indicate that Arkadia regulates metastasis in mouse models of breast cancer and melanoma. TGF-b signaling has both tumor-suppressive and tumor-promoting roles, and it is therefore difficult to target this pathway for cancer therapy (46) . Because Arkadia is an enzyme that is required for only a subset of TGF-b responses, it might be amenable to inhibition by small molecules, and thus represents a possible therapeutic target for cancer.
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